Edwards Lifesciences Corporation $EW Shares Acquired by Citigroup Inc.

Citigroup Inc. grew its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 30.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,385,415 shares of the medical research company’s stock after purchasing an additional 321,986 shares during the quarter. Citigroup Inc. owned 0.24% of Edwards Lifesciences worth $108,353,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth $266,000. Private Advisor Group LLC grew its stake in Edwards Lifesciences by 11.6% during the 1st quarter. Private Advisor Group LLC now owns 23,801 shares of the medical research company’s stock worth $1,725,000 after purchasing an additional 2,475 shares in the last quarter. IFP Advisors Inc grew its stake in Edwards Lifesciences by 113.6% during the 1st quarter. IFP Advisors Inc now owns 6,103 shares of the medical research company’s stock worth $442,000 after purchasing an additional 3,246 shares in the last quarter. J.W. Cole Advisors Inc. increased its holdings in Edwards Lifesciences by 220.2% during the 1st quarter. J.W. Cole Advisors Inc. now owns 11,224 shares of the medical research company’s stock worth $814,000 after purchasing an additional 7,719 shares during the period. Finally, Lindbrook Capital LLC raised its position in Edwards Lifesciences by 23.0% in the 1st quarter. Lindbrook Capital LLC now owns 5,159 shares of the medical research company’s stock valued at $374,000 after purchasing an additional 963 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Piper Sandler reissued an “overweight” rating and set a $95.00 price objective (up from $90.00) on shares of Edwards Lifesciences in a research report on Friday, October 31st. Oppenheimer cut shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. JPMorgan Chase & Co. increased their price objective on shares of Edwards Lifesciences from $85.00 to $90.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Robert W. Baird set a $83.00 price objective on shares of Edwards Lifesciences in a research report on Friday, October 31st. Finally, UBS Group reiterated a “neutral” rating and set a $90.00 target price on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $91.39.

Edwards Lifesciences Trading Down 0.7%

Shares of Edwards Lifesciences stock opened at $84.13 on Wednesday. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The company has a fifty day simple moving average of $78.37 and a 200-day simple moving average of $77.88. The stock has a market cap of $48.82 billion, a price-to-earnings ratio of 12.11, a PEG ratio of 3.97 and a beta of 1.03. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.21.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the previous year, the company earned $0.67 earnings per share. Edwards Lifesciences’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,816,265.10. The trade was a 4.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,314,725.84. The trade was a 24.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.